Gritstone bio (NASDAQ: GRTS) is expecting in the first quarter of 2024 preliminary data from its Phase 2/3 study evaluating the Company's personalized neoantigen vaccine candidate for the treatment of colorectal cancer...
THIS WEEK'S FEATURE
MORE FEATURES
NEWS
Just a few of the companies we’ve highlighted along the way
